12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zymafos palifosfamide: Development discontinued

Ziopharm discontinued development of Zymafos as first-line treatment of STS after the double-blind, international Phase III PICASSO 3 trial in 447 anthracycline-naïve patients with metastatic STS showed that IV Zymafos plus doxorubicin missed the primary endpoint of improving PFS vs. doxorubicin alone. Although recommended by the study's IDMC, Ziopharm said it does not plan to follow patients to evaluate the secondary endpoint of OS. Zymafos plus doxorubicin was well tolerated. The company said full data...

Read the full 353 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >